Whalesbook
Naye heights pe Park Medi World, acquisition aur profits ka jadoo!
Park Medi World ke share ne aaj stock market mein apna naya record banaya, 5.5% ka jump maar kar ₹179.55 ke 52-week high ko touch kiya. Trading volume bhi pehle se 1.06 times zyada dekha gaya, jo investors ka interest dikha raha hai.
Is rally ka sabse bada reason hai company ka ₹245 crore mein Agra mein KP Institute of Medical Sciences (KPIMS) ka acquisition. Ye 360-bed wala hospital chain ke Uttar Pradesh footprint ko aur strong karega, as company North India ki doosri sabse badi private hospital chain banne ki race mein hai. Plan hai ki March 2028 tak 5,260 beds tak pahunch jayen, jismein KPIMS jaise acquired hospitals bhi shaamil hain.
Q3 FY26 Results ne lagaya chaar chand!
Company ne apne Q3 FY26 ke results bhi release kiye hain, jismein sales 18% badhkar ₹410 crore ho gayi hai aur net profit 16% badhkar ₹52.80 crore raha hai. Aur agar 9 mahine ki baat karein (9MFY26), toh sales 17% badhkar ₹1,218.90 crore aur net profit 43% badhkar ₹196.80 crore raha hai. Wah! Itna strong performance dekh kar lagta hai ki company apni expansion plans ko seriously follow kar rahi hai.
Debt-free hone ki race mein aur Future ki planning
Company ne kaha hai ki woh February 2026 tak debt-free ho jayegi, jo ki ek bahut badi achievement hogi. Isse unki financial flexibility badhegi aur interest expenses kam honge. Analysts expect kar rahe hain ki ROCE 21% aur ROE 23% ke aas paas rahega jab acquired assets fully operational ho jayenge.
Valuation aur Risks ka kya scene hai?
Park Medi World ki market cap ab ₹7,600 crore ke aas paas hai aur P/E ratio 35-36x chal raha hai. Compare karein toh Apollo jaise bade players ke P/E 59-70x hain, aur Narayana Hrudayalaya ka 44.79x hai. Toh Park Medi World ka P/E thoda kam lag raha hai, but ek cheez dhyan dene wali hai ki unka Annual Revenue Per Operating Bed (ARPOB) industry leaders se kaafi kam hai. Yeh affordable care par focus karne ka nateeja ho sakta hai.
Par bhai, sab kuch itna bhi smooth nahi hai. Company ka 83% revenue government schemes se aata hai, jismein payment delays ka risk ho raha hai. Aur kuch analysts ne company ki quality ko 'below average' kaha hai aur valuation ko 'overvalued zone' mein bataya hai. Expansion plans ko execute karna bhi ek bada challenge hoga. Toh, sab dekho, par soch samajh kar invest karo!